powerful statement: " Zacks has only predicted a 2-3% market share. Even with that conservative, small percentage, and assuming a stable (not growing) addressable market of around a half a million patients stabilized on 8mg or less of buprenorphine, that's 10 to 15 thousand patients at two treatments a year (30,000 x $4,950 =$150 million). That should mean about $25 to $30 million in royalty income to Titan, with net earnings of about a buck a share."
News 
Market Data 
Discover 
AI
